Cost-effectiveness of liposomal irinotecan (nal-IRI) combined with 5-fluorouracil and leucovorin in second or subsequent lines for metastatic pancreatic cancer in Italy. It can be done

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology Pub Date : 2025-09-01 DOI:10.1016/j.pan.2025.08.007

Jacopo Giuliani , Daniela Mangiola , Giuseppe Napoli , Silvia Muraro , Marina Tommasi , Francesco Fiorica , Teodoro Sava

引用次数: 0

查看原文本刊更多论文

在意大利，伊立替康脂质体（nal-IRI）联合5-氟尿嘧啶和亚叶酸蛋白治疗转移性胰腺癌二线或后续治疗的成本-效果这是可以做到的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pancreatology 医学-胃肠肝病学

CiteScore

7.20

自引率

5.60%

发文量

194

审稿时长

44 days

期刊介绍： Pancreatology is the official journal of the International Association of Pancreatology (IAP), the European Pancreatic Club (EPC) and several national societies and study groups around the world. Dedicated to the understanding and treatment of exocrine as well as endocrine pancreatic disease, this multidisciplinary periodical publishes original basic, translational and clinical pancreatic research from a range of fields including gastroenterology, oncology, surgery, pharmacology, cellular and molecular biology as well as endocrinology, immunology and epidemiology. Readers can expect to gain new insights into pancreatic physiology and into the pathogenesis, diagnosis, therapeutic approaches and prognosis of pancreatic diseases. The journal features original articles, case reports, consensus guidelines and topical, cutting edge reviews, thus representing a source of valuable, novel information for clinical and basic researchers alike.